AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. Click here to find out ...

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) is expected to be releasing its earnings data before the market opens ...

A live webcast of both presentations can be accessed under "Events and Presentations" in the Investor section of the Company’s website, ...

Amylyx Pharmaceuticals (NASDAQ:AMLX) has priced a public offering of ~17.14M shares of its common stock at $3.50 a share. In addition, Amylyx has granted the underwriter a 30-day option to ...

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday, after review of the data from its phase 2 trial – was the next day ...

NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares ...

Amylyx Pharmaceuticals, Inc. (AMLX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten ...

Morningstar brands and products Company Portfolio ...